Reston, VA (January 16, 2026)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Interim PET Imaging as a Prognostic Tool in Large B-Cell Lymphoma
This meta-analysis of 44 studies examines whether interim ¹⁸F-FDG PET scans can predict treatment response, disease progression, and survival in patients with large B-cell lymphoma. The analysis compares diagnostic performance, imaging thresholds, and metabolic changes across thousands of patients undergoing therapy.
Targeting PSMA in Advanced Kidney Cancer
Clear cell renal cell carcinoma remains difficult to treat after standard therapies fail. This phase 2 trial evaluates the safety and effectiveness of the radiopharmaceutical ¹⁷⁷Lu-PSMA-617 in patients with advanced PSMA-positive disease, using PET imaging to guide treatment and assess tumor response, survival, and emerging biomarkers.
Nuclear Medicine Capacity and Growth Across Africa
This regional assessment examines nuclear medicine services in Africa, mapping infrastructure, imaging and therapy availability, and workforce challenges. Drawing on International Atomic Energy Agency data and professional surveys, it highlights uneven access, rapid PET/CT growth, limited advanced therapies, and ongoing efforts to expand imaging, treatment, and training capacity across the continent.
Comparing Two PET Tracers for Neuroendocrine Tumors
This head-to-head PET/CT study compares ⁶⁸Ga-DOTATATE and ⁶⁸Ga-NODAGA-LM3 in patients with neuroendocrine and related tumors. It evaluates normal-organ uptake, lesion detection, and tumor-to-background contrast, highlighting distinct distribution patterns and improved liver metastasis detection with NODAGA-LM3.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook
